Vaccine research and development: Assessment paper

RethinkHIV: Smarter Ways to Invest in Ending HIV in Sub-Saharan Africa

Volumn , Issue , 2009, Pages 299-334

  Hecht, Robert ^a   Jamison, Dean T ^b   Augenstein, Jared ^c   Partridge, Gabrielle ^a   Thorien, Kira ^a  

^a RESULTS FOR DEVELOPMENT INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889257240     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139236805.009     Document Type: Chapter

References (4)

1. Hecht, R., Bollinger, L., Stover, J., McGreevey, W., Muhib, F., Madavo, C. E. and De Ferranti, D. (2009). Critical choices in financing the response to the global HIV/AIDS pandemic. Health Affairs 28(6): 1591–605.
2. Hecht, R., Jamison, D. T., Augenstein, J., Partridge, G. and Thorien, K. Cost-benefit analysis of developing an AIDS vaccine for sub-Saharan Africa. [This volume.]
3. Hecht, R., Stover, J., Bollinger, L., Muhib, F., Case, K. and De Ferranti, D. (2010). Financing of HIV/AIDS programme scale-up in low-income and middle-income countries 2009–31. Lancet 376: 1254–60.
4. Institute for Health Metrics and Evaluation. (2010). Financing Global Health 2010: Development Assistance and Country Spending in Economic Uncertainty. Seattle, WA: IHME.